Scholar Rock Stock Declines Amid Disappointing Earnings Report
Scholar Rock's shares fell sharply after the biotech firm reported a wider-than-expected quarterly loss. The company posted no revenue and a net loss of $110 million, missing analyst estimates by a significant margin. Rising administrative costs, which nearly tripled year-over-year, drove the deeper deficit.
Despite the financial setback, Scholar Rock maintains a cash position of $295 million, which it claims will fund operations into 2027. The earnings release included a business update hinting at potential catalysts, including progress with the U.S. Food and Drug Administration.